PCOS Gets a New Name: Experts Rename Condition PMOS to Better Reflect Its Nature
Global health experts announced in May 2026 that Polycystic Ovary Syndrome, known as PCOS, will be renamed Polycystic Metabolic Ovarian Syndrome, or PMOS. The new name is intended to better reflect the metabolic nature of the condition and improve diagnosis and care for the millions of women affected. Advocates say the change could reduce misdiagnosis and help patients get appropriate treatment sooner.
Global health experts announced in May 2026 that Polycystic Ovary Syndrome, widely known as PCOS, will be renamed Polycystic Metabolic Ovarian Syndrome, or PMOS.
The name change follows years of advocacy from researchers, clinicians, and patient groups who argued that the original name was misleading. Not all women with the condition have polycystic ovaries, and the name failed to capture the metabolic dysfunction that is central to the disorder.
PCOS, now PMOS, affects an estimated 8 to 13 percent of women of reproductive age worldwide. It is one of the most common hormonal disorders in women and a leading cause of infertility. Symptoms include irregular periods, excess androgen levels, and in some cases, cysts on the ovaries.
The metabolic aspects of the condition, including insulin resistance, elevated blood sugar, and increased risk of type 2 diabetes, are often as significant as the reproductive symptoms. Experts say the new name will help clinicians recognize and treat these metabolic components more consistently.
Advocates for the name change say it could also reduce the time it takes for women to receive a correct diagnosis. Many women with the condition spend years seeing multiple doctors before getting answers, partly because the name and diagnostic criteria have been confusing.
The announcement was welcomed by patient advocacy organizations, which have long pushed for clearer language around the condition. Some groups noted that the name change alone will not solve the broader problem of underdiagnosis and inadequate care, but they called it an important step.
Researchers are also working on updated clinical guidelines to accompany the new name. These guidelines are expected to place greater emphasis on metabolic screening and treatment, alongside the reproductive health aspects of the condition.
The name change will take effect across medical literature and clinical practice over the coming months as professional organizations update their standards.
